Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)

Inclusion Criteria: * Adult subjects with Ph+ ALL in CHR (1st or 2nd) with MRD positivity confirmed at baseline, older or equal to 60 years or not eligible for other post-CHR treatment modalities. * WHO score 0-1. * Hematopoietic, liver and renal normal functions defined as follows: WBC bigger or equal to 2.000/mm3 lymphocytes bigger or equal to 500/mm3 neutrophils bigger or equal to 1.000/mm3 platelets bigger or equal to 50.000/mm3 Hb bigger or equal to 9 g/dl creatinine fewer or equal to 1.5 x ULN bilirubin fewer or equal to 1.5 x ULN AST and ALT less than 3 times the upper limit of normal. LDH less than 2 times the upper limit of normal. * For male and female subjects of childbearing potential, agreement to use effective contraception. * Authorization by Istituto Superiore di Sanità (ISS) according to DM 2 March 2004. * Signed written informed consent according to ICH/EU/GCP and national local regulations. Exclusion Criteria: * Concurrent chemotherapy or immunotherapy (TKI maintenance is permitted). * Any contraindications to perform a leukapheretic procedure for mononuclear cell collection. * Active or chronic infection, including Treponema, HIV, HBV and/or HCV unless antigen/PCR negative. * Presence of autoimmune symptoms. * Pregnant or lactating females. * Simultaneous participation in another clinical trial. * Any physical or psychological impediment in a patient that could lead the investigator to suspect his/her poor compliance to the protocol.